Introduction
Luzitin, S.A. is a pharmaceutical company focused on the pursuit of innovative solutions for photodynamic therapy (PDT).
Our Mission and Strategy
Our mission is to investigate and develop innovative photosensitizing compounds to be used in Photodynamic Therapy (PDT) or Photodynamic Diagnosis (PDD) of cancer.
A new generation of photodynamic sensitizers for the treatment of solid tumors
Luzitin is seeking financing and/or a partnership to:
- Advance LUZ-51 or second-generation Redaporfin (Redaporfin 2.0) to IND readiness.
- Conduct a Phase 1b/2a study.
Scientific highlights
- Next generation photosensitizers were designed rationally to overcome limitations of previous photosensitizers.
- Three generations of photosensitizers patented and published in world-leading journals.
- Rapid onset of action allows for photosensitizer administration in operating room (instead of several days in advance).
- Potential to be applied in multiple tumor types.
- Unlike surgery, it is a targeted therapy which preserves vital structures and can be repeated if necessary.
Synergy with Immunotherapy
- Preclinical data suggest Redaporfin increases PD-L1 expression, potentially enhancing the efficacy of immune checkpoint inhibitors.
Initial clinical data de-risk further development
- Phase 1 study in a population of heavily pre-treated patients with head and neck cancer showed promising results.
- Best-in-class safety profile among photodynamic therapies.
- Dose-dependent efficacy signal observed.
- Minimum effective dose established.
